COG ANBL1232 - Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Objective

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.

https://clinicaltrials.gov/ct2/show/NCT02176967?term=anbl1232&rank=1

Location:

Essentia Health Duluth

Disclosures:

None

For more information about a financial conflict of interest (FCOI) or to review the Essentia Health FCOI policy, click here.

Last Updated: 05/12/2015

Research Study Categories

  • Pediatric Studies

Specialty

  • Rare Tumor
  • Cancer
Contact
Cancer Clinical Trials at 218-786-3308